← Back to Search

Behavioral Intervention

Active SCAR Intervention for Social Anxiety

N/A
Waitlist Available
Research Sponsored by Ohio University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Score ≥ 6 on the social concerns subscale of the Anxiety Sensitivity Index-3 OR score ≥ 2 on the Social Phobia Scale-6
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one month post intervention.
Awards & highlights
No Placebo-Only Group

Summary

Social anxiety disorder (SAD) is a prominent mental health burden, affecting more than 24 million Americans annually. Social anxiety is worsened by social isolation and severe, ongoing stress. Therefore, it is expected that the COVID-19 pandemic will significantly increase social anxiety symptoms and related impairment. Left untreated, social anxiety typically has a chronic course and a substantial impact on wellbeing. Despite the considerable impact of social anxiety, treatment for social anxiety is underutilized compared to other anxiety disorders, likely due to the distress socially anxious individuals experience upon presenting to treatment. Thus, treatments that are accessible and effective in treating social anxiety are needed. One potential to augment existing treatments for SAD is to develop brief, single-session interventions that could be administered virtually. These interventions could then be combined with additional technological innovations, such as ecological momentary intervention (EMI), to reduce social anxiety. Further, interventions targeting causal risk factors for social anxiety may be particularly beneficial, as these approaches could be used in both prevention and treatment efforts. One risk factor that represents an ideal target for interventions is anxiety sensitivity social concerns (ASSC), defined as the fear of publicly observable symptoms of anxiety (i.e., blushing, trembling, sweating). Although ASSC has been shown to be a risk factor for social anxiety, no interventions have been developed to target ASSC. In the proposed study, a brief (1 hour) virtual intervention targeting ASSC using Cognitive-Behavioral Therapy (CBT) techniques will be developed through examining the acceptability and feasibility of the SCAR intervention prototype. The proposed project holds the promise of developing an intervention to reliably reduce the impact of ASSC, both as a standalone intervention and in combination with other therapeutic approaches.

Eligible Conditions
  • Social Anxiety

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month post intervention.
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month post intervention. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Client Satisfaction Questionnaire-8
Ecological Momentary Intervention Completion Rate
Secondary study objectives
Anxiety Sensitivity Index-3
Social Interaction Anxiety Scale-6
Social Phobia Scale-6
Other study objectives
Alcohol Use Disorders Identification Test
Attentional Control Scale - Straightforward
Brief Fear of Negative Evaluation-II
+11 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Waitlist ControlActive Control1 Intervention
Participants assigned to the waitlist control condition will complete baseline measures and measures one month following their baseline appointment. After they complete the follow-up measures, they will be offered the SCAR intervention.
Group II: Active SCAR InterventionActive Control1 Intervention
In this arm, participants will complete baseline measures, receive the SCAR intervention, and complete follow-up measures one month following the intervention.

Find a Location

Who is running the clinical trial?

Ohio UniversityLead Sponsor
71 Previous Clinical Trials
37,175 Total Patients Enrolled
~9 spots leftby Nov 2025